4591
RIBOMIC Inc.
リボミック
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Non-consolidated
Key metrics
Revenue(thousand JPY)
Mar 2022
80,909
Mar 2023
65,969
Mar 2024
-
Mar 2025
2,107
Mar 2026
3,000
Operating profit(thousand JPY)
Mar 2022
-1,748,112
Mar 2023
-1,786,041
Mar 2024
-1,116,193
Mar 2025
-1,050,589
Mar 2026
-1,207,132
Operating profit margin(%)
Mar 2022
-2,160.59
Mar 2023
-2,707.39
Mar 2024
-
Mar 2025
-49,861.84
Mar 2026
-40,237.73
Profit before tax(thousand JPY)
Mar 2022
-1,683,544
Mar 2023
-1,651,792
Mar 2024
-1,023,027
Mar 2025
-1,017,729
Mar 2026
-1,144,150
Profit(thousand JPY)
Mar 2022
-1,684,754
Mar 2023
-1,653,002
Mar 2024
-1,024,237
Mar 2025
-1,018,939
Mar 2026
-1,145,360
Total assets(thousand JPY)
Mar 2022
4,954,476
Mar 2023
4,583,655
Mar 2024
3,547,257
Mar 2025
3,185,842
Mar 2026
2,976,215
Cash and cash equivalents(thousand JPY)
Mar 2022
2,901,796
Mar 2023
2,825,182
Mar 2024
2,099,743
Mar 2025
1,837,123
Mar 2026
1,927,180
Cash flows from operating activities(thousand JPY)
Mar 2022
-1,499,224
Mar 2023
-1,708,626
Mar 2024
-932,757
Mar 2025
-996,966
Mar 2026
-1,110,863
Cash flows from investing activities(thousand JPY)
Mar 2022
689,556
Mar 2023
276,353
Mar 2024
177,272
Mar 2025
67,178
Mar 2026
289,832
Cash flows from financing activities(thousand JPY)
Mar 2022
354,721
Mar 2023
1,333,771
Mar 2024
27,649
Mar 2025
667,263
Mar 2026
911,054
Return on equity(-)
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Mar 2026
-
Equity ratio(%)
Mar 2022
94.7
Mar 2023
95.7
Mar 2024
95.5
Mar 2025
95.5
Mar 2026
95.4
Earnings per share(JPY per share)
Mar 2022
-59.95
Mar 2023
-53.14
Mar 2024
-28.7
Mar 2025
-25.21
Mar 2026
-23.07
Net assets per share(JPY per share)
Mar 2022
164.33
Mar 2023
122.85
Mar 2024
94.09
Mar 2025
68.26
Mar 2026
52.3
Dividend per share(-)
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Mar 2026
-
Payout ratio(-)
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Mar 2026
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.